慢性乙型肝炎HBeAg阴性患者抗病毒治疗停药后临床观察

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (770 KB) HTML (0 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the patterns of viral responses and changes of alanine aminotransferase (ALT) levels in HBeAg-negative patients one year after withdrawal of antiviral drugs.Methods The clinical data on HBeAg negative chronic hepatitis B patients (CHB) who took nucleotide analogues (NAs) and met the inclusion criteria was collected in our hospital. The clinical characteristics at the time of withdrawal of NAs and one year after treatment were analyzed. Results From January 2017 to July 2020, there were 40 CHB patients who met the inclusion criteria, 19 of whom were HBeAg positive and 21 were HBeAg negative. HBeAg-negative patients were more likely to have their HBV DNA rebounded(P=0.031) and ALT elevated(P=0.017) than HBeAg- positive patients after withdrawal of NAs. HBeAg-negative patients with rebounding HBV DNA after withdrawal of NAs had their HBsAg titers gradually decreased in the 1st month, 3rd month, 6th month, and 12th month. There was statistically significant difference compared with the HBV DNA-negative group. The ALT levels of patients with rebounding HBV DNA gradually increased, but hepatitis B reoccurred only in one patient.Conclusions One year after withdrawal of NAs, the rebound rate of HBV DNA is high and the ALT level is elevated in HBeAg negative patients.For patients with rebounding HBV DNA, HBsAg titers are decreased, which might contribute to the clearance of HBsAg in the long run.

Key words： chronic hepatitis B HBeAg negative drug withdrawal

Received: 07 April 2021

ZTFLH:

R575.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Dali
	FENG Danni
	HE Xi
	QU Mengmeng
	WANG Fuchuan
	WANG Pu
	YAN Jianguo
	LIU Jiaye
	ZHANG Min
	GAO Yinjie

Cite this article:

ZHANG Dali,FENG Danni,HE Xi等. Clinical observation of patients with HBeAg negative chronic hepatitis B after withdrawal of antiviral drugs[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2021, 32(8): 671-675.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2021/V32/I8/671

[1]	Sarin S K, Kumar M, Lau G K, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update[J]. Hepatol Int,2016,10(1):1-98.
[2]	Lampertico P, Agarwal K, Berg T, et al. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2):370-398.
[3]	Terrault N A, Lok A S F, McMahon B J, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4):1560-1599.
[4]	Chang M L, Liaw Y F, Hadziyannis S J. Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B[J]. Aliment Pharmacol Ther, 2015, 42(3):243-257.
[5]	Hadziyannis S J, Sevastianos V, Rapti I, et al. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir[J]. Gastroenterology, 2012,143(3):629-636 e1.
[6]	Berg T, Simon K-G, Mauss S, et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients-FINITE study[J]. J Hepatol, 2017, 67(5):918-924.
[7]	Jeng W J, Chen Y C, Chien R N, et al. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B[J]. Hepatology, 2018, 68(2):425-434.
[8]	Liaw Y F, Jeng W J, Chang M L. HBsAg Kinetics in Retreatment Decision for Off-Therapy Hepatitis B Flare in HBeAg-Negative Patients[J]. Gastroenterology,2018,154(8):2280-2281.
[9]	Yeo Y H, Ho H J, Yang H I, et al. Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis[J]. Gastroenterology, 2019,156(3):635-646.
[10]	Downs L O, Smith D A, Lumley S F, et al. Electronic Health Informatics Data To Describe Clearance Dynamics of Hepatitis B Surface Antigen (HBsAg) and e Antigen (HBeAg) in Chronic Hepatitis B Virus Infection[J]. mBio,2019,10(3):e00699-19.
[11]	Jeng W J, Chang M L, Liaw Y F. Off-therapy precipitous HBsAg decline predicts HBsAg loss after finite entecavir therapy in HBeAg-negative patients[J]. J Viral Hepat, 2019, 26(8):1019-1026.
[12]	Liaw Y F. Hepatitis B flare after cessation of nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B: To retreat or not to retreat[J]. Hepatology, 2021,73(2):843-852.
[13]	Oliveri F, Surace L, Cavallone D, et al. Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance[J]. Liver Int, 2017, 37(11):1622-1631.
[14]	Ghany M G, Feld J J, Chang K M, et al. Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad[J]. Lancet Gastroenterol Hepatol, 2020, 5(4):406-417.
[15]	Liaw Y F, Tai D I, Chu C M, et al. Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody-positive patients[J]. Hepatology, 1987, 7(1):20-23.
[16]	Jeng W J, Chen Y C, Sheen I S, et al. Clinical Relapse After Cessation of Tenofovir Therapy in Hepatitis B e Antigen-Negative Patients[J]. Clin Gastroenterol Hepatol, 2016, 14(12):1813-1820 .
[17]	Liaw Y F, Jeng W J. Benefit of stopping finite nucleos(t)ide analogues therapy in chronic hepatitis B patients[J]. Gut, 2020, 69(10):1898-1899.
[18]	Le Bert N, Gill U S, Hong M, et al. Effects of Hepatitis B Surface Antigen on Virus-Specific and Global T Cells in Patients With Chronic Hepatitis B Virus infection[J]. Gastroenterology, 2020, 159(2):652-664.
[19]	Wang H, Luo H, Wan X, et al. TNF-alpha/IFN-gamma profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection[J]. J Hepatol, 2020, 72(1):45-56.
[20]	Kefalakes H, Jochum C, Hilgard G, et al. Decades after recovery from hepatitis B and HBsAg clearance the CD8+ T cell response against HBV core is nearly undetectable[J]. J Hepatol, 2015, 63(1):13-19.
[21]	Tan AT, Koh S, Goh W, et al. A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B[J]. J Hepatol, 2010, 52(3):330-339.
[22]	Chuaypen N, Posuwan N, Chittmittraprap S, et al. Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy[J]. Clin Microbiol Infect, 2018, 24(3):306 e7-306 e13.
[23]	Wang Y, Ying L, Jin K K, et al. Adenosine A(2A) receptor activation reverses hypoxiainduced rat pulmonary artery smooth muscle cell proliferation via cyclic AMPmediated inhibition of the SDF1CXC4 signaling pathway[J]. Int J Mol Med, 2018, 42(1):607-614.
[24]	Zimmer C L, Rinker F, Honer Zu Siederdissen C, et al. Increased NK Cell Function After Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated With Liver Damage and HBsAg Loss[J]. J Infect Dis, 2018, 217(10):1656-1666.
[25]	Nishio A, Bolte F J, Takeda K, et al. Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection[J]. Sci Transl Med, 2021,13(587):eaba6322.
[26]	Rinker F, Zimmer C L, Honer Z S, et al. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B[J]. J Hepatol, 2018, 69(3):584-593.